Summary
4.15 -0.21(-4.71%)05/10/2024
Sutro Biopharma Inc (STRO)
Sutro Biopharma Inc (STRO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 8.73 | 24.93 | -10.65 | -9.89 | 61.64 | -22.86 | -59.04 | -72.14 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.24 | |
| Open | 3.90 | |
| High | 4.25 | |
| Low | 3.90 | |
| Volume | 500,642 | |
| Change | 0.34 | |
| Change % | 8.73 | |
| Avg Volume (20 Days) | 533,580 | |
| Volume/Avg Volume (20 Days) Ratio | 0.94 | |
| 52 Week Range | 2.01 - 6.13 | |
| Price vs 52 Week High | -30.91% | |
| Price vs 52 Week Low | 110.70% | |
| Range | 8.59 | |
| Gap Up/Down | -0.07 | |
Fundamentals | ||
| Market Capitalization (Mln) | 339 | |
| EBIDTA | -36,933,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 32.38 | |
| Book Value | 6.1300 | |
| Earnings Per Share | -2.8450 | |
| EPS Estimate Current Quarter | -0.6300 | |
| EPS Estimate Next Quarter | -0.6200 | |
| EPS Estimate Current Year | -2.1600 | |
| EPS Estimate Next Year | -3.0500 | |
| Diluted EPS (TTM) | -2.8450 | |
| Revenues | ||
| Profit Marging | -2.1336 | |
| Operating Marging (TTM) | -1.4336 | |
| Return on asset (TTM) | -0.1571 | |
| Return on equity (TTM) | -0.4812 | |
| Revenue TTM | 59,504,000 | |
| Revenue per share TTM | 1.3340 | |
| Quarterly Revenue Growth (YOY) | -0.5220 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -34,239,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.3887 | |
| Revenue Enterprise Value | 8.5066 | |
| EBITDA Enterprise Value | 41.7130 | |
| Shares | ||
| Shares Outstanding | 46,270,300 | |
| Shares Float | 44,070,655 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 10.51 | |
| Institutions (%) | 90.57 | |
04/05 18:31 EST - Seeking Alpha
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
03/25 19:31 EST - Zacks Investment Research
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
Sutro Biopharma, Inc. (STRO) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.82 per share. This compares to loss of $0.61 per share a year ago.
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
Sutro Biopharma, Inc. (STRO) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.82 per share. This compares to loss of $0.61 per share a year ago.
03/21 10:56 EST - Zacks Investment Research
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
Sutro Biopharma (STRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
Sutro Biopharma (STRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
02/28 05:41 EST - Zacks Investment Research
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
02/06 16:05 EST - GlobeNewsWire
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.
12/14 16:05 EST - GlobeNewsWire
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host an investor webcast to highlight the broad opportunity for its foundational ADC program, Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC which has now shown clinical activity in three different tumor types to date. The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET featuring presentations by members of Sutro's senior management team and external key opinion leaders in oncology; and concluding with a Q&A session.
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host an investor webcast to highlight the broad opportunity for its foundational ADC program, Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC which has now shown clinical activity in three different tumor types to date. The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET featuring presentations by members of Sutro's senior management team and external key opinion leaders in oncology; and concluding with a Q&A session.
11/13 09:47 EST - Zacks Investment Research
Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
10/09 09:48 EST - Seeking Alpha
Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching
Sutro Biopharma is advancing its lead candidate, luvelta, for the treatment of various types of cancer, with a focus on ovarian and endometrial cancers. The company will present results from a phase 1b study using luvelta to treat endometrial cancer at the ESMO Congress 2023, which could indicate its potential for ovarian cancer treatment. Sutro Biopharma has enough cash to fund its operations until the first half of 2025, with cash and investments of $358.3 million as of June 30, 2023.
Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching
Sutro Biopharma is advancing its lead candidate, luvelta, for the treatment of various types of cancer, with a focus on ovarian and endometrial cancers. The company will present results from a phase 1b study using luvelta to treat endometrial cancer at the ESMO Congress 2023, which could indicate its potential for ovarian cancer treatment. Sutro Biopharma has enough cash to fund its operations until the first half of 2025, with cash and investments of $358.3 million as of June 30, 2023.
08/10 19:46 EST - Zacks Investment Research
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.55 per share a year ago.
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.55 per share a year ago.
05/15 10:41 EST - Zacks Investment Research
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.84 per share a year ago.
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.84 per share a year ago.
05/08 08:00 EST - GlobeNewsWire
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15th, 2023, at 2:00 p.m. ET / 11:00 a.m. PT in New York City.
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15th, 2023, at 2:00 p.m. ET / 11:00 a.m. PT in New York City.
05/04 05:21 EST - Zacks Investment Research
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?
Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?
Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
04/11 13:17 EST - Seeking Alpha
Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting
STRO is playing second fiddle to perpetually second fiddle player ImmunoGen in ovarian cancer. Although there are certain positive aspects to the molecule, I see little traction here.
Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting
STRO is playing second fiddle to perpetually second fiddle player ImmunoGen in ovarian cancer. Although there are certain positive aspects to the molecule, I see little traction here.
03/30 20:01 EST - Zacks Investment Research
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
03/01 08:00 EST - GlobeNewsWire
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in an Ovarian Cancer panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET / 6:10 a.m. PT in Boston, MA.
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in an Ovarian Cancer panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET / 6:10 a.m. PT in Boston, MA.
01/04 08:00 EST - GlobeNewsWire
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.
09/01 07:00 EST - GlobeNewsWire
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wells Fargo Healthcare Conference on Friday, September 9, 2022, at 10:25 a.m. ET / 7:25 a.m. PT in Boston.
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wells Fargo Healthcare Conference on Friday, September 9, 2022, at 10:25 a.m. ET / 7:25 a.m. PT in Boston.
08/16 01:05 EST - Seeking Alpha
Sutro Biopharma: Partnership Progress Warrants Exposure
Shares of Sutro Biopharma have lost one-third of their value over the past 3 years. Consolidation in the antibody drug conjugate space has made it an attractive area for drug development.
Sutro Biopharma: Partnership Progress Warrants Exposure
Shares of Sutro Biopharma have lost one-third of their value over the past 3 years. Consolidation in the antibody drug conjugate space has made it an attractive area for drug development.